Quantitative proteomic analysis of tumor reversion in multiple myeloma cells

Journal of Proteome Research

Volumn 10, Issue 2, 2011, Pages 845-855

  Ge, Feng ^a   Zhang, Liang ^b   Tao, Sheng Ce ^c   Kitazato, Kaio ^d   Zhang, Zhi Ping ^e   Zhang, Xian En ^e   Bi, Li Jun ^f  

^a INSTITUTE OF HYDROBIOLOGY   (China)

^b Singapore Health Research Facilities   (Singapore)

^c Shanghai Jiao Tong University   (China)

^d NAGASAKI UNIVERSITY   (Japan)

^e WUHAN INSTITUTE OF VIROLOGY   (China)

^f INSTITUTE OF BIOPHYSICS   (China)

Author keywords

Multiple myeloma (MM); Signal transducer and activator of transcription 3 (STAT3); Stable isotope labeling by amino acids in cell culture (SILAC); Tumor reversion

Indexed keywords

BAG2 PROTEIN; CDC2 PROTEIN; PCNA PROTEIN; PROTEIN; STAT3 PROTEIN; TRANSLATIONALLY CONTROLLED TUMOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FUNCTIONAL PROTEOMICS; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MULTIPLE MYELOMA; MYELOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERTANT; RNA INTERFERENCE;

CELL LINE, TUMOR; H-1 PARVOVIRUS; HUMANS; ISOTOPE LABELING; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NEOPLASTIC PROCESSES; PHENOTYPE; PROTEOME; PROTEOMICS; RNA INTERFERENCE; STAT3 TRANSCRIPTION FACTOR; TUMOR MARKERS, BIOLOGICAL;

H-1 PARVOVIRUS;

EID: 79955432526     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr100992e     Document Type: Article

References (65)

1. Mitsiades, C. S.; Mitsiades, N.; Munshi, N. C; Anderson, K. C. Focus on multiple myeloma. Cancer Cell 2004, 6 (5), 439-44. (Pubitemid 39469979)
2. Kyle, R. A.; Rajkumar, S. V. Monoclonal gammopathy of undetermined significance. Br. J. Haematol. 2006, 134 (6), 573-89. (Pubitemid 44255500)
3. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin. 2008, 58 (2), 71-96.
4. Barlogie, B.; Shaughnessy, J.; Tricot, G.; Jacobson, J.; Zangari, M.; Anaissie, E.; Walker, R.; Crowley, J. Treatment of multiple myeloma. Blood 2004, 103 (1), 20-32. (Pubitemid 38029914)
5. Tassone, P.; Tagliaferri, P.; Rossi, M.; Gaspari, M.; Terracciano, R.; Venuta, S. Genetics and molecular profiling of multiple myeloma: novel tools for clinical management. Eur. J. Cancer 2006, 42 (11), 1530-8. (Pubitemid 44118767)
6. Hideshima, T.; Mitsiades, C.; Tonon, G.; Richardson, P. G.; Anderson, K. C. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat. Rev. Cancer 2007, 7 (8), 585-98. (Pubitemid 47106630)
7. Telerman, A.; Amson, R. The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat. Rev. Cancer 2009, 9 (3), 206-16.
8. Telerman, A.; Tuynder, M.; Dupressoir, T.; Robaye, B.; Sigaux, F.; Shaulian, E.; Oren, M.; Rommelaere, J.; Amson, R. A model for tumor suppression using H-1 parvovirus. Proc. Natl. Acad. Sci. U.S.A. 1993, 90 (18), 8702-6. (Pubitemid 23277738)
9. Nemani, M.; Linares-Cruz, G.; Bruzzoni-Giovanelli, H.; Roperch, J. P.; Tuynder, M.; Bougueleret, L.; Cherif, D.; Medhioub, M.; Pasturaud, P.; Alvaro, V.; der Sarkissan, H.; Cazes, L.; Le Paslier, D.; Le Gall, I.; Israeli, D.; Dausset, J.; Sigaux, F.; Chumakov, I.; Oren, M.; Calvo, F.; Amson, R. B.; Cohen, D.; Telerman, A. Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 1996, 93 (17), 9039-42. (Pubitemid 26282014)
10. Linares-Cruz, G.; Bruzzoni-Giovanelli, H.; Alvaro, V.; Roperch, J. P.; Tuynder, M.; Schoevaert, D.; Nemani, M.; Prieur, S.; Lethrosne, F. ; Piouffre, L.; Reclar, V.; Faille, A.; Chassoux, D.; Dausset, J.; Amson, R. B.; Calvo, F.; Telerman, A. p21WAF-1 reorganizes the nucleus in tumor suppression. Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (3), 1131-5.
11. Tuynder, M.; Susini, L.; Prieur, S.; Besse, S.; Fiucci, G.; Amson, R.; Telerman, A. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc. Natl. Acad. Sci. U.S.A. 2002, 99 (23), 14976-81. (Pubitemid 35334595)
12. Tuynder, M.; Fiucci, G.; Prieur, S.; Lespagnol, A.; Geant, A.; Beaucourt, S.; Duflaut, D.; Besse, S.; Susini, L.; Cavarelli, J.; Moras, D.; Amson, R.; Telerman, A. Translationally controlled tumor protein is a target of tumor reversion. Proc. Natl. Acad. Sci. U.S.A. 2004, 101 (43), 15364-9. (Pubitemid 39441547)
13. Braun, A. C. Recovery of tumor cells from effects of the tumorinducing principle in crown gall. Science 1951, 113 (2945), 651-3.
14. Braun, A. C. A Demonstration of the Recovery of the Crown-Gall Tumor Cell with the Use of Complex Tumors of Single-Cell Origin. Proc. Natl. Acad. Sci. U.S.A. 1959, 45 (7), 932-8.
15. Pierce, G. B.; Dixon, F. J., Jr. Testicular teratomas. I. Demonstration of teratogenesis by metamorphosis of multipotential cells. Cancer 1959, 12 (3), 573-83.
16. Seilern-Aspang, F.; Kratochwil, K. Induction and differentiation of an epithelial tumour in the newt (Triturus cristatus). J. Embryol. Exp. Morphol. 1962, 10, 337-56.
17. Noda, M.; Kitayama, H.; Matsuzaki, T.; Sugimoto, Y.; Okayama, H.; Bassin, R. H.; Ikawa, Y. Detection of genes with a potential for suppressing the transformed phenotype associated with activated ras genes. Proc. Natl. Acad. Sci. U.S.A. 1989, 86 (1), 162-6. (Pubitemid 19036348)
18. Kitayama, H.; Sugimoto, Y.; Matsuzaki, T.; Ikawa, Y.; Noda, M. A ras-related gene with transformation suppressor activity. Cell 1989, 56 (1), 77-84. (Pubitemid 19033515)
19. Ryuya, M.; Teruyuki, M.; Emi, N.; Yoko, M.; Hitoshi, K.; Shinae, K.; Yoshinori, K.; Masahiro, H.; Motonari, U.; Makoto, N. A novel screen using the Reck tumor suppressor gene promoter detects both conventional and metastasis-suppressing anticancer drugs. Oncotarget 2010, 1 (4), 12.
20. Susini, L.; Besse, S.; Duflaut, D.; Lespagnol, A.; Beekman, C.; Fiucci, G. ; Atkinson, A. R.; Busso, D.; Poussin, P.; Marine, J. C.; Martinou, J. C.; Cavarelli, J.; Moras, D.; Amson, R.; Telerman, A. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 2008, 15 (8), 1211-20. (Pubitemid 351984751)
21. Lespagnol, A.; Duflaut, D.; Beekman, C.; Blanc, L.; Fiucci, G.; Marine, J. C.; Vidal, M.; Amson, R.; Telerman, A. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008, 15 (11), 1723-33.
22. Cans, C.; Passer, B. J.; Shalak, V.; Nancy-Portebois, V.; Crible, V.; Amzallag, N.; Allanic, D.; Tufino, R.; Argentini, M.; Moras, D.; Fiucci, G.; Goud, B.; Mirande, M.; Amson, R.; Telerman, A. Translationally controlled tumor protein acts as a guanine nucleotide dissociation inhibitor on the translation elongation factor eEF1A. Proc. Natl. Acad. Sci. U.S.A. 2003, 100 (24), 13892-7. (Pubitemid 37499162)
23. Ong, S. E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D. B.; Steen, H. ; Pandey, A.; Mann, M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 2002, 1 (5), 376-86.
24. Chen, N.; Sun, W.; Deng, X.; Hao, Y.; Chen, X.; Xing, B.; Jia, W.; Ma, J.; Wei, H.; Zhu, Y.; Qian, X.; Jiang, Y.; He, F. Quantitative proteome analysis of HCC cell lines with different metastatic potentials by SILAC. Proteomics 2008, 8 (23-24), 5108-18.
25. Sun, Y.; Mi, W.; Cai, J.; Ying, W.; Liu, F.; Lu, H.; Qiao, Y.; Jia, W.; Bi, X.; Lu, N.; Liu, S.; Qian, X.; Zhao, X. Quantitative proteomic signature of liver cancer cells: tissue transglutaminase 2 could be a novel protein candidate of human hepatocellular carcinoma. J Proteome Res. 2008, 7 (9), 3847-59.
26. Kratchmarova, I.; Blagoev, B.; Haack-Sorensen, M.; Kassem, M.; Mann, M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005, 308 (5727), 1472-7. (Pubitemid 40791302)
27. Blagoev, B.; Ong, S. E.; Kratchmarova, I.; Mann, M. Temporal analysis of phosphotyrosine-dependent signaling networks by quantitative proteomics. Nat. Biotechnol. 2004, 22 (9), 1139-45. (Pubitemid 39166852)
28. Zhang, L.; Zhang, Z. P.; Zhang, X. E.; Lin, F. S.; Ge, F. Quantitative proteomics analysis reveals BAG3 as a potential target to suppress severe acute respiratorysyndrome coronavirus replication. J. Virol. 2010, 84 (12), 6050-9.
29. Ge, F.; Lu, X. P.; Zeng, H. L.; He, Q. Y.; Xiong, S.; Jin, L.; He, Q. Y. Proteomic and functional analyses reveal a dual molecular mechanism underlying arsenic-induced apoptosis in human multiple myeloma cells. J. Proteome Res. 2009, 8 (6), 3006-19.
30. St-Germain, J. R.; Taylor, P.; Tong, J.; Jin, L. L.; Nikolic, A.; Stewart, I. I.; Ewing, R. M.; Dharsee, M.; Li, Z.; Trudel, S.; Moran, M. F. Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc. Natl. Acad. Sci. U.S.A. 2009, 106 (47), 20127-32.
31. Rees-Unwin, K. S.; Craven, R. A.; Davenport, E.; Hanrahan, S.; Totty, N. F.; Dring, A. M.; Banks, R. E.; G, J. M.; Davies, F. E. Proteomic evaluation of pathways associated with dexamethasonemediated apoptosis and resistance in multiple myeloma. Br. J. Haematol. 2007, 139 (4), 559-67. (Pubitemid 350043814)
32. Chen, Y. Q.; de Foresta, F.; Hertoghs, J.; Avalosse, B. L.; Cornelis, J. J.; Rommelaere, J. Selective killing of simian virus 40-transformed human fibroblasts by parvovirus H-1. Cancer Res. 1986, 46 (7), 3574-9. (Pubitemid 16096911)
33. Dagvadorj, A.; Tan, S. H.; Liao, Z.; Cavalli, L. R.; Haddad, B. R.; Nevalainen, M. T. Androgen-regulated and highly tumorigenic human prostate cancer cell line established from a transplantable primary CWR22 tumor. Clin. Cancer Res. 2008, 14 (19), 6062-72.
34. Park, S. K.; Venable, J. D.; Xu, T.; Yates, J. R., III. A quantitative analysis software tool for mass spectrometry-based proteomics. Nat. Methods 2008, 5 (4), 319-22. (Pubitemid 351459367)
35. Mi, H.; Guo, N.; Kejariwal, A.; Thomas, P. D. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res. 2007, 35 (Database issue), D247-52. (Pubitemid 46056208)
36. Nikitin, A.; Egorov, S.; Daraselia, N.; Mazo, I. Pathway studio-the analysis and navigation of molecular networks. Bioinformatics 2003, 19 (16), 2155-7. (Pubitemid 37408171)
37. Chatterjee, M.; Stuhmer, T.; Herrmann, P.; Bommert, K.; Dorken, B.; Bargou, R. C. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004, 104 (12), 3712-21. (Pubitemid 39564449)
38. Matsuoka, Y.; Moore, G. E.; Yagi, Y.; Pressman, D. Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc. Soc. Exp. Biol. Med. 1967, 125 (4), 1246-50.
39. Hendrix, M. J.; Seftor, E. A.; Seftor, R. E.; Kasemeier-Kulesa, J.; Kulesa, P. M.; Postovit, L. M. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 2007, 7 (4), 246-55. (Pubitemid 46480969)
40. Kulesa, P. M.; Kasemeier-Kulesa, J. C.; Teddy, J. M.; Margaryan, N. V.; Seftor, E. A.; Seftor, R. E.; Hendrix, M. J. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (10), 3752-7. (Pubitemid 43376627)
41. Shapiro-Shelef, M.; Calame, K. Regulation of plasma-cell development. Nat. Rev. Immunol. 2005, 5 (3), 230-42. (Pubitemid 40364824)
42. Asosingh, K.; De Raeve, H.; Croucher, P.; Goes, E.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+)5T multiple myeloma cells. Exp. Hematol. 2001, 29 (1), 77-84. (Pubitemid 32054769)
43. Asosingh, K.; Willems, A.; Van Riet, I.; Van Camp, B.; Vanderkerken, K. Delayed in vivo disease progression is associated with high proportions of CD45+ myeloma cells in the 5T2MM murine model. Cancer Res. 2003, 63 (12), 3019-20. (Pubitemid 36735843)
44. Vanderkerken, K.; Asosingh, K.; Croucher, P.; Van Camp, B. Multiple myeloma biology: lessons from the 5TMM models. Immunol. Rev. 2003, 194, 196-206. (Pubitemid 36896125)
45. Yaccoby, S. The phenotypic plasticity of myeloma plasma cells as expressed by dedifferentiation into an immature, resilient, and apoptosis-resistant phenotype. Clin. Cancer Res. 2005, 11 (21), 7599-606. (Pubitemid 41611599)
46. Anastasiadou, E.; Vaeth, S.; Cuomo, L.; Boccellato, F.; Vincenti, S.; Cirone, M.; Presutti, C.; Junker, S.; Winberg, G.; Frati, L.; Wade, P. A.; Faggioni, A.; Trivedi, P. Epstein-Barr virus infection leads to partial phenotypic reversion ofterminallydifferentiated malignant B cells. Cancer Lett. 2009, 284 (2), 165-74.
47. Zhan, F.; Barlogie, B.; Arzoumanian, V.; Huang, Y.; Williams, D. R.; Hollmig, K.; Pineda-Roman, M.; Tricot, G.; van Rhee, F.; Zangari, M.; Dhodapkar, M.; Shaughnessy, J. D., Jr. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 2007, 109 (4), 1692-700. (Pubitemid 46239604)
48. Yenofsky, R.; Bergmann, I.; Brawerman, G. Messenger RNAspecies partially in a repressed state in mouse sarcoma ascites cells. Proc. Natl. Acad. Sci. U.S.A. 1982, 79 (19), 5876-80. (Pubitemid 13199993)
49. MacDonald, S. M.; Rafnar, T.; Langdon, J.; Lichtenstein, L. M. Molecular identification of an IgE-dependent histamine-releasing factor. Science 1995, 269 (5224), 688-90.
50. Schroeder, J. T.; Lichtenstein, L. M.; MacDonald, S. M. Recombinant histamine-releasing factor enhances IgE-dependent IL-4 and IL-13 secretion by human basophils. J. Immunol. 1997, 159 (1), 447-52. (Pubitemid 127493731)
51. Vonakis, B. M.; Macglashan, D. W., Jr.; Vilarino, N.; Langdon, J. M.; Scott, R. S.; MacDonald, S. M. Distinct characteristics of signal transduction events by histamine-releasing factor/translationally controlled tumor protein (HRF/TCTP)-induced priming and activation of human basophils. Blood 2008, 111 (4), 1789-96.
52. Gachet, Y.; Tournier, S.; Lee, M.; Lazaris-Karatzas, A.; Poulton, T.; Bommer, U. A. The growth-related, translationally controlled protein P23 has properties of a tubulin binding protein and associates transiently with microtubules during the cell cycle. J. Cell Sci. 1999, 112 (Pt 8), 1257-71. (Pubitemid 29218914)
53. Burgess, A.; Labbe, J. C.; Vigneron, S.; Bonneaud, N.; Strub, J. M.; Van Dorsselaer, A.; Lorca, T.; Castro, A. Chfr interacts and colocalizes with TCTP to the mitotic spindle. Oncogene 2008, 27, 5554-5566.
54. Li, F.; Zhang, D.; Fujise, K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 2001, 276 (50), 47542-9.
55. Liu, H.; Peng, H. W.; Cheng, Y. S.; Yuan, H. S.; Yang-Yen, H. F. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol. Cell. Biol. 2005, 25 (8), 3117-26. (Pubitemid 40464314)
56. Yang, Y.; Yang, F.; Xiong, Z.; Yan, Y.; Wang, X.; Nishino, M.; Mirkovic, D.; Nguyen, J.; Wang, H.; Yang, X. F. An N-terminal region of translationally controlled tumor protein is required for its antiapoptotic activity. Oncogene 2005, 24 (30), 4778-88. (Pubitemid 41076295)
57. Hsu, Y. C.; Chern, J. J.; Cai, Y.; Liu, M.; Choi, K. W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 2007, 445 (7129), 785-8. (Pubitemid 46279709)
58. Levy, D. E.; Darnell, J. E., Jr. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3 (9), 651-62. (Pubitemid 34987786)
59. Al Zaid Siddiquee, K.; Turkson, J. STAT3 as a target for inducing apoptosis in solid and hematological tumors. Cell Res. 2008, 18 (2), 254-67. (Pubitemid 351206162)
60. Germain, D.; Frank, D. A. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin. Cancer Res. 2007, 13 (19), 5665-9. (Pubitemid 47583890)
61. Seita, J.; Asakawa, M.; Ooehara, J.; Takayanagi, S.; Morita, Y.; Watanabe, N.; Fujita, K.; Kudo, M.; Mizuguchi, J.; Ema, H.; Nakauchi, H.; Yoshimoto, T. Interleukin-27 directly induces differentiation in hematopoietic stem cells. Blood 2008, 111 (4), 1903-12. (Pubitemid 351451499)
62. Alvarez, J. V.; Febbo, P. G.; Ramaswamy, S.; Loda, M.; Richardson, A.; Frank, D. A. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res. 2005, 65 (12), 5054-62. (Pubitemid 40827313)
63. Yu, H.; Kortylewski, M.; Pardoll, D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7 (1), 41-51. (Pubitemid 46020826)
64. Turkson, J.; Jove, R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19 (56), 6613-26. (Pubitemid 32197700)
65. Deng, J.; Grande, F.; Neamati, N. Small molecule inhibitors of Stat3 signaling pathway. Curr. Cancer Drug Targets 2007, 7 (1), 91-107. (Pubitemid 46345511)